X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator, which is being evaluated for the treatment of platinum-resistant ARID1a-mutated ovarian cancer.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
The collaboration aims to evaluate NXP800, an oral small molecule, in an Investigator-sponsored clinical trial in cholangiocarcinoma. The FDA granted Orphan Drug Designation for the treatment of cholangiocarcinoma.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2023
Details:
NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The IND has been cleared by the FDA and a Phase 1a dose escalation study is pending commencement.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers. It is being investigated in platinum-resistant, ARID1a-mutated ovarian carcinoma.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ENGOT
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2023
Details:
The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1a study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical with IND studies ongoing.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
NXP800 is an HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900 is a novel SRC/YES1 kinase inhibitor currently in IND-enabling studies.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The HSF1 signaling pathway plays an important role in the initiation and progression of many cancers.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
In preclinical studies, NXP800 demonstrated potent anti-proliferative activity against a variety of cancer cell lines, and inhibited tumor growth in ARID1A-mutated ovarian clear cell carcinoma and ovarian endometrioid carcinoma human xenograft models.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical development with IND-enabling studies ongoing.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway, that plays an important role in the initiation and progression of many cancers, is currently in a Phase 1 clinical study.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Institute of Cancer Research in London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The Company intends to use the proceeds to fund the Phase 1/2 development of NXP800, the IND-enabling studies of NXP900, to continue development and sponsored research related to its current product candidates.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 04, 2022
Details:
The Phase 1 study for NXP800, comprised of two parts: Phase 1a dose-escalation will evaluate the safety and tolerability in patients with advanced solid tumors and, Phase 1b will evaluate preliminary efficacy in specific populations.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 31, 2021
Details:
Nuvectis also announced that it has licensed exclusive worldwide rights to develop and commercialize the drug candidate NXP800, a novel, oral small molecule inhibitor of the heat shock factor 1 (HSF1) pathway from the CRT Pioneer Fund LP .
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sixth Element Capital
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
